HW
RGNX icon

Hancock Whitney’s Regenxbio RGNX Stock Holding History

Hancock Whitney’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,062
Closed -$470K – 833
2020
Q3 		$470K Sell
17,062
-2,490
-13% -$81.2K 0.02% 526
2020
Q2 		$720K Sell
19,552
-4,478
-19% -$167K 0.03% 430
2020
Q1 		$778K Buy
+24,030
New +$1M 0.03% 420

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Korea Investment Corp
Korea Investment Corp Seoul, South Korea $48.3B AUM 31.57% 1-Year Est. Return

Hancock Whitney's RGNX Position: Q4 2020 in Review

Hancock Whitney sold out of Regenxbio (RGNX) in Q4 2020, closing a stake of 17,062 shares — an estimated $470K sold.

Hancock Whitney first reported a position in RGNX in Q1 2020 and held it in 3 quarters. The position peaked at $778K in Q1 2020. 187 funds tracked by Wall St. Rank hold RGNX as of Q4 2020.

  • Hancock Whitney reported no remaining Regenxbio position as of Q4 2020 after selling out during the quarter.
  • Hancock Whitney sold 17,062 Regenxbio shares in Q4 2020, an estimated $470K.
  • Hancock Whitney first reported a position in Regenxbio in Q1 2020 and held it in 3 quarters.
  • Hancock Whitney's Regenxbio position peaked at $778K in Q1 2020.
  • 187 funds tracked by Wall St. Rank held Regenxbio as of Q4 2020.

Based on Hancock Whitney's 13F filing for Q4 2020, filed 9 Feb 2021.